About the AG

  • Subscribe to the AG's RSS Feed
  • Join the AG's FaceBook
  • Follow the AG on Twitter
  • View the AG's YouTube Channel

Clinical Drug Trials

  1. The Research Advisory Panel requires all single or multicenter clinical drug trial protocols involving Schedule I and Schedule II controlled substances as a main study drug to be submitted by the sponsor conducting the study to the Panel for review and approval prior to the start-up of any sites in California. Clinical Drug Trials Sponsors include pharmaceutical companies, NIH, NIDA, NARC, etc. Below is the items required for Panel review:

    1. Cover Letter

      The cover letter should be in the form of a request letter, from the sponsor conducting the single or multicenter clinical trial study, for Panel review of the protocol to be used in the study. It should include:

      • The title of the study
      • An anticipated startup and completion time lines
      • The number of California sites planned, and estimated number of subjects
      • The name, mailing address, phone number, and e-mail address of a contact person of the sponsor or CRO.
    2. Research Protocol
    3. Template Informed Consent Form: See California Informed Consent Form Guidelines

    4. Investigators Brochure(IB)
    5. List of each California site's address and Principle Investigator (PI)'s name and e-mail address (No CV required)
  2. The Research Advisory Panel grants the approval to the Sponsor or CRO conducting the clinical drug trial, not the individual PI's or sites participating in the study. Therefore, the Sponsor or CRO conducting the clinical drug trial is required to submit the study applications to the Panel, not the individual PI's or sites participating in the study.

  3. Research studies shall not be started, research subjects cannot be enrolled or screened, before the Panel’s approval.

Megan's Law

California Registered Sex Offender Database

Search Now

Site Navigation

Translate Website

  • Google™ Translation Disclaimer

This Google™ translation feature is provided for informational purposes only.

The Office of the Attorney General is unable to guarantee the accuracy of this translation and is therefore not liable for any inaccurate information resulting from the translation application tool.

Please consult with a translator for accuracy if you are relying on the translation or are using this site for official business.

If you have any questions please contact:Bilingual Services Program at (916) 324-5482

A copy of this disclaimer can also be found on our Disclaimer page.

Select a Language Below / Seleccione el Idioma Abajo

Close this box or use the [ X ]